Tempest Therapeutics, Inc. 8-K — AI Bull & Bear Analysis

Tempest Therapeutics is currently fighting a two-front battle to maintain its Nasdaq listing, citing both a failure to meet minimum stockholders' equity requirements and a collapse of its independent board structure. While the company has until July 6, 2026, to submit a compliance plan, the lack of a cure period for its board vacancies increases the urgency. The overall impact is a high-volatility scenario where the company's survival depends on its ability to rapidly secure funding and reconstitute its leadership under extreme time pressure.